Gemcitabine, Nab-paclitaxel Plus the TheraBionic P1 (an Amplitude-Modulated Radiofrequency Electromagnetic Fields) Device to Treat Metastatic Pancreatic Cancer
Public ClinicalTrials.gov record NCT06576115. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Treatment of Patients With Metastatic Pancreatic Cancer With Gemcitabine and Nab-Paclitaxel and Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF)
Study identification
- NCT ID
- NCT06576115
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Enrollment
- 30 participants
Conditions and interventions
Conditions
Interventions
- Nab paclitaxel Drug
- Gemcitabine Drug
- TheraBionic P1 Device
Drug · Device
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 27, 2025
- Primary completion
- Jun 30, 2027
- Completion
- Jun 30, 2027
- Last update posted
- Nov 4, 2025
2025 – 2027
United States locations
- U.S. sites
- 7
- U.S. states
- 1
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Karmanos Cancer Institute at McLaren Clarkston | Clarkston | Michigan | 48346 | Recruiting |
| Karmanos Cancer Institute | Detroit | Michigan | 48021 | Recruiting |
| Karmanos Cancer Institute at McLaren Flint | Flint | Michigan | 48532 | Recruiting |
| Karmanos Cancer Institute at McLaren Greater Lansing | Lansing | Michigan | 48910 | Recruiting |
| Karmanos Cancer Institute at McLaren Lapeer Region | Lapeer | Michigan | 48446 | Recruiting |
| Karmanos Cancer Institute at McLaren Northern Michigan, Petoskey | Petoskey | Michigan | 49770 | Recruiting |
| Karmanos Cancer Institute at McLaren Port Huron | Port Huron | Michigan | 48060 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06576115, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 4, 2025 · Synced Jun 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06576115 live on ClinicalTrials.gov.